Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada

References

• Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics 2016. Toronto, ON: Canadian Cancer Society; 2016; [cited 2022 March 24]. Available from: www.cancer.ca/Canadian-Cancer-Statistics-2016-EN.pdf.
   Google Scholar
• Malone S, Shayegan B, Basappa NS, et al. Management algorithms for metastatic prostate cancer. Can Urol Assoc J. 2019;14(2):50–60.
   Web of Science ®Google Scholar
• de Oliveira C, Bremner KE, Pataky R, et al. Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open. 2013;1(4):E151–E158.
   PubMedGoogle Scholar
• So AI, Chi KN, Danielson B, et al. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Can Urol Assoc J. 2020;14(2):17–23.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Chen YH, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73(6):847–855.
   PubMed Web of Science ®Google Scholar
• Danielson B, Saad F, So A, et al. Management algorithms for prostate-specific antigen progression in prostate cancer: biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. Can Urol Assoc J. 2019;13(12):420–426.
   PubMed Web of Science ®Google Scholar
• Appukkuttan S, Tangirala K, Babajanyan S, et al. A retrospective claims analysis of advanced prostate cancer costs and resource use. Pharmacoecon Open. 2020;4(3):439–447.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Mulani PM, Fishman M, et al. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16(4):571–575.
   PubMed Web of Science ®Google Scholar
• Schaeffer E, Srinivas S, Antonarakis ES, et al. Prostate cancer, version 3.2022, NCCN clinical practice guidelines in oncology: National Comprehensive Cancer Network. 2022; [cited 2022 February 23] Available from https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
   Google Scholar
• Saad F, Canil C, Finelli A, et al. Controversial issues in the management of patients with advanced prostate cancer: results from a Canadian consensus forum. Can Urol Assoc J. 2020;14(4):E137–E149.
   PubMed Web of Science ®Google Scholar
• Alberta Health Services. Advanced/metastatic prostate cancer. 2018; [April 2021]. Available from: https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu010-met-prostate.pdf.
   Google Scholar
• Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801.
   PubMed Web of Science ®Google Scholar
• Weiner AB, Nettey OS, Morgans AK. Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm. Curr Treat Options Oncol. 2019;20(9):69.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Dunshee C, De Giorgi U, et al. Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study. Eur Urol. 2020;78(4):603–614.
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada, CADTH. 2017. Available from: https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition.
   Google Scholar
• Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. BMC Cancer. 2021;21(1):35.
   PubMed Web of Science ®Google Scholar
• Beca J, Majeed H, Chan KKW, et al. Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. Can Urol Assoc J. 2019;13(12):396–403.
   PubMed Web of Science ®Google Scholar
• Rashid M, Ramesh M, Shamshavali K, et al. Efficacy and safety of non-steroidal anti-androgens in patients with metastatic prostate cancer: meta-analysis of randomized controlled trials. Rev Recent Clin Trials. 2020;15(1):34–47.
   PubMed Web of Science ®Google Scholar
• Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(18):1755–1756.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Skaltsa K, Longworth L, Ivanescu C, et al. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer. Value Health. 2014;17(2):238–244.
   PubMed Web of Science ®Google Scholar
• Wang L, Paller C, Hong H, et al. Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. J Natl Cancer Inst. 2022;114(2):191–202.
   PubMedGoogle Scholar
• Schedule of Benefits for Laboratory Services: Ministry of Health, Ontario Health Insurance Plan Laboratories and Genetics Branch 2020. Available from: https://health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2020.pdf.
   Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). G Ital Cardiol (Rome). 2017;18(7):547–612.
   Google Scholar
• Ontario Drug Benefit Formulary/Comparative Drug Index. 2021. Available from: https://www.formulary.health.gov.on.ca/formulary/.
   Google Scholar
• Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report-Part I. Value Health. 2010;13(1):3–7.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jr., Mansley EC, Abbott TA, 3rd, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report-Part II. Value Health. 2010;13(1):8–13.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. 2014. Available from: https://www.nice.org.uk/process/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869.
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network Meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Chen J, Ni Y, Sun G, et al. Comparison of current systemic combination therapies for metastatic hormone-sensitive prostate cancer and selection of candidates for optimal treatment: a systematic review and Bayesian network meta-analysis. Front Oncol. 2020;10:519388.
   PubMed Web of Science ®Google Scholar
• Mori K, Mostafaei H, Sari Motlagh R, et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 2021;129(4):423–433.
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77(3):365–372.
   PubMed Web of Science ®Google Scholar
• Komura K, Sweeney CJ, Inamoto T, et al. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25(3):220–231.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4):290–308.
   PubMed Web of Science ®Google Scholar
• Siegel DA, O’Neil ME, Richards TB, et al. Prostate cancer incidence and survival, by stage and race/ethnicity – United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473–1480.
   PubMed Web of Science ®Google Scholar